How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study.

Autor:	Cherrez-Ojeda I; Universidad Espíritu Santo, Samborondón, Ecuador.; Respiralab, Respiralab Research Group, Guayaquil, Ecuador., Vanegas E; Universidad Espíritu Santo, Samborondón, Ecuador.; Respiralab, Respiralab Research Group, Guayaquil, Ecuador., Cherrez A; Respiralab, Respiralab Research Group, Guayaquil, Ecuador.; Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany., Felix M; Universidad Espíritu Santo, Samborondón, Ecuador.; Respiralab, Respiralab Research Group, Guayaquil, Ecuador., Weller K; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany., Magerl M; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany., Maurer RR; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany., Mata VL; Universidad Espíritu Santo, Samborondón, Ecuador.; Respiralab, Respiralab Research Group, Guayaquil, Ecuador., Kasperska-Zajac A; European Center for Diagnosis and Treatment of Urticaria, Medical University of Silesia, Katowice, Poland., Sikora A; European Center for Diagnosis and Treatment of Urticaria, Medical University of Silesia, Katowice, Poland., Fomina D; City Center of Allergy and Immunology, Clinical City Hospital #52, Moscow, Russia.; Department of Allergology and Clinical Immunology, I.M. Sechenov First Moscow State Medical University, Trubetskaya St., 8/2, Moscow, 119991, Russian Federation., Kovalkova E; City Center of Allergy and Immunology, Clinical City Hospital #52, Moscow, Russia., Godse K; Department of Dermatology, D Y, Patil University School of Medicine and Hospital, Mumbai, India., Rao ND; Department of Dermatology, D Y, Patil University School of Medicine and Hospital, Mumbai, India., Khoshkhui M; Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.; Department of Allergy and Immunology, Mashhad University of Medical Sciences, Mashhad, Iran., Rastgoo S; Department of Allergy and Immunology, Mashhad University of Medical Sciences, Mashhad, Iran., Criado RF; Department of Dermatology, Faculdade de Medicina do ABC, São Paulo, Brazil., Abuzakouk M; Allergy and Immunology Department, Cleveland Clinic Abu Dhabi, United Arab Emirates., Grandon D; Allergy and Immunology Department, Cleveland Clinic Abu Dhabi, United Arab Emirates., Van Doorn MBA; Department of Dermatology, Erasmus MC, Rotterdam, the Netherlands., Oliveira Rodrigues Valle S; Department of Internal Medicine, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil., De Souza Lima EM; Faculty of Science and Health of Juiz de Fora - SUPREMA, Minas Gerais, Brazil., Thomsen SF; Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Biomedical Sciences, Copenhagen, Denmark., Ramón GD; Instituto de Alergia e Inmunología del Sur, Bahía Blanca, Prov. De Buenos Aires, Argentina., Matos Benavides EE; Centro de Referencia de Alergia, Asma e Inmunología - Instituto Nacional del Niño, Lima, Perú., Bauer A; Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany., Giménez-Arnau AM; Department of Dermatology, Hospital del Mar, IMIM, Universitat Autònoma, Barcelona, Spain., Kocatürk E; Department of Dermatology, Koç University School of Medicine, Istanbul, Turkey., Guillet C; Department of Dermatology, University Hospital Zurich, Switzerland., Larco JI; Allergy Department, Clinica San Felipe, Lima, Peru., Zhao ZT; Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China., Makris M; Allergy Unit, 2nd Department of Dermatology and Venereology, National and Kapodistrian, University of Athens, 'Attikon' University Hospital, Greece., Ritchie C; Allergy Division, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Xepapadaki P; Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Greece., Ensina LF; Federal University of São Paulo. São Paulo, Brazil., Cherrez S; Respiralab, Respiralab Research Group, Guayaquil, Ecuador.; Department of Dermatology, SRH Zentralklinikum Suhl, Germany., Maurer M; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany.
Jazyk:	angličtina
Zdroj:	The World Allergy Organization journal [World Allergy Organ J] 2021 Jun 04; Vol. 14 (6), pp. 100542. Date of Electronic Publication: 2021 Jun 04 (Print Publication: 2021).
DOI:	10.1016/j.waojou.2021.100542
Abstrakt:	Background: Patients with chronic urticaria (CU) are increasingly using information and communication technologies (ICTs) to manage their health. What CU patients expect from ICTs and which ICTs they prefer remains unknown. We assessed why CU patients use ICTs, which ones they prefer, and what drives their expectations and choices. Methods: In this cross-sectional study, 1841 patients across 17 countries were recruited at UCAREs (Urticaria Centers of Reference and Excellence). Patients with CU who were >12 years old completed a 23-item questionnaire. Results: Most patients were interested in receiving disease information (87.3%), asking physicians about CU (84.1%), and communicating with other patients through ICTs (65.6%). For receiving disease information, patients preferred one-to-one and one-to-many ICTs, especially web browsers. One-to-one ICTs were also the ICTs of choice for asking physicians about urticaria and for communicating with other patients, and e-mail and WhatsApp were the preferred ICTs, respectively. Many-to-many ICTs such as Facebook, Instagram, LinkedIn, and Twitter were least preferred for all 3 purposes. Living in rural areas and higher education were linked to higher odds of being interested in receiving disease information, asking physicians, and communicating with patients through ICTs. Conclusions: Most patients and especially patients with higher education who live in rural areas are interested in using ICTs for their healthcare, but prefer different ICTs for different purposes, ie, web browsers for obtaining information, e-mail for asking physicians, and WhatsApp for communicating with other patients. Our findings may help to improve ICTs for CU. Competing Interests: I Cherrez-Ojeda has no conflicts of interest. E Vanegas has no conflicts of interest. A Cherrez has no conflicts of interest. M Felix has no conflicts of interest. K Weller is or recently was a speaker and/or advisor for, and/or has received research funding from: Biocryst, CSL Behring, Dr. Pfleger, FAES, Moxie, Novartis, Shire/Takeda, and Uriach. M Magerl is or recently was a speaker and/or advisor for, and/or has received research funding from Biocryst, CSL Behring, Kalvista Pharmaceuticals, Moxie, Novartis, Pharming, and Shire/Takeda. RR Maurer has no conflicts of interest. VL Mata has no conflicts of interest. A Kasperska-Zajac has no conflicts of interest. A Sikora has no conflicts of interest. D Fomina is or recently was a speaker and/or advisor for, and/or has received research funding from: AstraZeneca, CSL Behring, Glaxo SmithKline, MSD, Novartis, Sanofi, and Shire/Takeda. E Kovalkova has no conflicts of interest. K Godse has no conflicts of interest. N Dheeraj Rao has no conflicts of interest. M Khoshkhui has no conflicts of interest. S Rastgoo has no conflicts of interest. RFJ Criado has no conflicts of interest. M Abuzakouk has no conflicts of interest. D Grandon has no conflicts of interest. MBA van Doorn is or recently was a speaker and/or advisor for, and/or has received research funding from Abbvie, BMS, Celgene, Janssen Cilag, LEO Pharma, Lilly, MSD, Novartis, Pfizer, and Sanofi-Genzyme. S Valle has no conflicts of interest. E Magalhães de Souza Lima has no conflicts of interest. SF Thomsen is or recently was a speaker and/or advisor for, and/or has received research funding from: Abbvie, AstraZeneca, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pierre Fabre, Roche, Sanofi, and UCB. GD Ramón has no conflicts of interest. EE Matos Benavides has no conflicts of interest. A Bauer is or recently was a speaker and/or advisor for, and/or has received research funding from Novartis, Sanofi, Genentech, Leo Pharma and Shire/Takeda. Ana M Giménez-Arnau has held roles as a Medical Advisor for Sanofi, Uriach, Genentech, Novartis, Amgen , ThemoFisher, Roche, Almirall, and has research grants supported by Instituto Carlos III- FEDER, Novartis, and Uriach; she also participates in educational activities for Almirall, Genentech, Glaxo SmithKline, LEO Pharma, Menarini, MSD, Novartis, Sanofi, Avene and Uriach. E Kocatürk is or recently was a speaker and/or advisor for Bayer, Novartis, and Sanofi. C Guillet has no conflicts of interest. JI Larco is or recently was a speaker and/or advisor for: FAES, Novartis, and Sanofi. Z-T Zhao has no conflicts of interest. M Makris is or recently was a speaker and/or advisor for, and/or has received research funding from AstraZeneca, Chiesi, Glaxo SmithKline, Novartis, and Sanofi. C Ritchie has no conflicts of interest. P Xepapadak reports personal fees from Galenica Greece, Glaxo SmithKline, Nestle, Novartis, Nutricia, and Uriach, outside the submitted work. LF Ensina is or recently was a speaker and/or advisor for, and/or has received research funding from Novartis, Sanofi, and Takeda. S Cherrez has no conflicts of interest. M Maurer is or recently was a speaker and/or advisor for, and/or has received research funding from: Allakos, Alnylam, Aralez, AstraZeneca, Biocryst, Blueprint, CSL Behring, FAES, Genentech, Kalvista Pharmaceuticals, LEO Pharma, Menarini, Moxie, MSD, Novartis, Pharming, Pharvaris, Roche, Sanofi, Shire/Takeda, UCB, and Uriach. (© 2021 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu